Catalent (CTLT)
(Delayed Data from NYSE)
$59.86 USD
-0.28 (-0.47%)
Updated Sep 25, 2024 04:00 PM ET
After-Market: $59.87 +0.01 (0.02%) 7:58 PM ET
1-Strong Buy of 5 1
C Value A Growth D Momentum B VGM
- YR Estimate
- 06/30/2023
- 06/30/2022
- 06/30/2021
- 06/30/2020
- 06/30/2019
- Revenue - Line of Business (LOBR)
- Revenue: Biologics
- 1,984.00
- 2,534.00
- 1,938.00
- --
- --
- Revenue - Line of Business (LOBR)
- Revenue: Pharma and Consumer Health
- 2,294.00
- 2,271.00
- 2,063.00
- --
- --
- Revenue - Line of Business (LOBR)
- Revenue: Inter-segment revenue elimination
- -2.00
- -17.00
- -3.00
- -10.00
- -14.00
- Revenue - Geographic (GEOR)
- Geographic Revenues: United States
- 2,782.00
- 3,110.00
- 2,462.00
- 1,822.00
- 1,317.30
- Revenue - Geographic (GEOR)
- Geographic Revenue: Europe
- 1,256.00
- 1,506.00
- 1,343.00
- 976.00
- 842.10
- Revenue - Geographic (GEOR)
- Geographic Revenue: Other International
- 355.00
- 327.00
- 288.00
- 376.00
- 433.80
- Revenue - Geographic (GEOR)
- Elimination of revenue
- -117.00
- -115.00
- -95.00
- -80.00
- -75.20
- Income - Line of Business (LOBI)
- Segment EBITDA: Biologics
- 287.00
- 777.00
- 615.00
- 237.00
- --
- Income - Line of Business (LOBI)
- Segment EBITDA: Pharma and Consumer Health
- 555.00
- 589.00
- 498.00
- --
- --
- Income - Line of Business (LOBI)
- Segment EBITDA: Unallocated costs
- -551.00
- -286.00
- 1.00
- -146.00
- --
- Non Financial / Operating Metric (NFM)
- Organic Revenue Growth
- -11.00
- 20.00
- 25.00
- --
- --